会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Inhalable gaseous medicament based on xenon and nitrous oxide
    • 基于氙气和一氧化二氮的可吸入气体药物
    • US20070053992A1
    • 2007-03-08
    • US10563278
    • 2004-07-23
    • Jacques AbrainiMarc Lemaire
    • Jacques AbrainiMarc Lemaire
    • A61K33/00
    • A61K33/00A61K2300/00
    • The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurin, GABA, noradrenaline and/or any other neurotransmitter. The proportion by volume of xenon of the mixture ranges between 5 and 45%, and the proportion by volume of nitrous oxide ranges between 10 and 50%, the balance is preferably oxygen.
    • 本发明涉及使用含有气体氙气和一氧化二氮气体以及有利地为氧气的气体混合物,用于制备用于预防或治疗人类神经毒素的全部或部分可吸入药物。 本发明的氙/一氧化二氮混合物作用于一种或多种脑受体,以减少多巴胺,谷氨酸,血清素,牛磺酸,GABA,去甲肾上腺素和/或任何其他神经递质的释放和/或作用。 混合物的氙的体积比例为5〜45%,一氧化二氮的体积比为10〜50%,余量优选为氧。
    • 2. 发明申请
    • Argon-based inhalable gaseous medicinal product for the treatment of neurointoxications
    • 氩气可吸入气体药物治疗神经毒素
    • US20050152988A1
    • 2005-07-14
    • US11007684
    • 2004-12-08
    • Marc LemaireJacques Abraini
    • Marc LemaireJacques Abraini
    • A61K33/00C01B23/00
    • A61K33/00
    • The invention relates to the use of argon (Ar) gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neuro-transmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.
    • 本发明涉及氩(Ar)气用于生产旨在预防或治疗人类神经毒素的全部或部分可吸入药物的用途。 药用产品含有有效比例的氩气,作用于至少一种脑受体,以调节多巴胺,谷氨酸,5-羟色胺,乙酰胆碱,牛磺酸,GABA和/或去甲肾上腺素介导的神经传递的功能 系统。 优选地,气态医药产品中的氩气体积比例为15-80%。 神经排毒选自产生成瘾状态,急性脑意外,神经变性疾病,精神病学或神经病理学,特别是焦虑症,精神病状况,特别是精神分裂症和各种形式的癫痫的兴奋性毒性。
    • 3. 发明申请
    • Argon-based inhalable gaseous medicinal product for the treatment of neurointoxications
    • 氩气可吸入气体药物治疗神经毒素
    • US20070275089A1
    • 2007-11-29
    • US11836536
    • 2007-08-09
    • Marc LemaireJacques Abraini
    • Marc LemaireJacques Abraini
    • A61K33/00A61P43/00
    • A61K33/00
    • The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.
    • 本发明涉及使用氩气来生产旨在预防或治疗人类神经毒素的全部或部分可吸入药物。 药用产品含有有效比例的氩气,并且作用于至少一种脑受体,以调节多巴胺,谷氨酸,5-羟色胺,乙酰胆碱,牛磺酸,GABA和/或去甲肾上腺素介导的神经传递系统的功能。 优选地,气态医药产品中的氩气体积比例为15-80%。 神经排毒选自产生成瘾状态,急性脑意外,神经变性疾病,精神病学或神经病理学,特别是焦虑症,精神病状况,特别是精神分裂症和各种形式的癫痫的兴奋性毒性。
    • 4. 发明申请
    • Inhalable Gaseous Medicament Based On Xenon And Nitrous Oxide
    • 基于氙气和一氧化二氮的可吸入气体药物
    • US20090252816A1
    • 2009-10-08
    • US12417087
    • 2009-04-02
    • Jacques AbrainiMarc Lemaire
    • Jacques AbrainiMarc Lemaire
    • A61K33/00
    • A61K33/00A61K2300/00
    • The invention concerns the use of a gaseous mixture containing gas xenon and gas nitrous oxide, and advantageously oxygen, for making all or part of an inhalable medicine for preventing or treating neurointoxication in a human. The xenon/nitrous oxide mixture of the invention acts on one or more cerebral receptors to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurin, GABA, noradrenaline and/or any other neurotransmitter. The proportion by volume of xenon of the mixture ranges between 5 and 45%, and the proportion by volume of nitrous oxide ranges between 10 and 50%, the balance is preferably oxygen.
    • 本发明涉及使用含有气体氙气和一氧化二氮气体以及有利地为氧气的气体混合物,用于制备用于预防或治疗人类神经毒素的全部或部分可吸入药物。 本发明的氙/一氧化二氮混合物作用于一种或多种脑受体,以减少多巴胺,谷氨酸,血清素,牛磺酸,GABA,去甲肾上腺素和/或任何其他神经递质的释放和/或作用。 混合物的氙的体积比例为5〜45%,一氧化二氮的体积比为10〜50%,余量优选为氧。